Foscenvivint

Foscenvivint (PRI 724 or OP 724) is a CREB-binding protein/β-catenin inhibitor that is developed for the treatment of liver diseases such as primary biliary cholangitis, hepatocellular carcinoma, and hepatitis C and B virus-induced liver cirrhosis.